Form 4: Telesis Bio Inc. Director Steven J. Golub Acquires Shares and Stock Options

Director Steven J. Golub acquired 8,390 shares of common stock and 5,268 stock options in Telesis Bio Inc. on July 24, 2024.

Summary

• On July 24, 2024, Steven J. Golub, a director of Telesis Bio Inc., acquired 8,390 shares of common stock.
• These shares were obtained as restricted stock units (RSUs), each representing a contingent right to receive one share of Telesis Bio Inc.'s common stock.
• The vesting schedule for 3,512 RSUs is one-third on each annual anniversary of the grant date (July 24, 2024), while 4,878 RSUs will vest fully on January 1, 2025, contingent upon continued service.
• Golub also acquired 5,268 stock options with an exercise price of $4.10.
• These options vest in equal monthly installments following the grant date (July 24, 2024) over a three-year period, also contingent upon continued service.
• Following these transactions, Golub directly owns 8,390 shares of common stock and 5,268 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing reflecting insider transactions. The acquisition of shares and options can be seen as a positive sign, but it's not necessarily indicative of significant positive news.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future prospects.
• The vesting schedules for the RSUs and stock options incentivize the director to remain with the company and contribute to its success.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The transaction could have a slightly positive impact on shareholders as it signals confidence from a company director.

Key Dates

Keywords

Form 4, insider trading, stock options, restricted stock units, director, Steven J. Golub, Telesis Bio Inc., TBIO, beneficial ownership